GlueTacs Therapeutics is a clinical stage biotech developing molecular glue degraders and PROTACs, as well as degrader-antibody conjugates. Our novel intellectual property enables best-in-class substrate specificity, and our library accelerates discovery. Altogether, our systematic approach integrates virtual design, synthesis, and substrate evaluation to unlock pathways previously deemed "undruggable", producing an unpartnered pipeline focused on refractory tumors and immune diseases.